| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1cc4d6ffab1778d0021b8f79793fb40e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-577 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40 |
| filingDate |
2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbd594f6d7da781eb1a66d018aaede98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_761b3fa59592577fdf422967c2713616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75be38a651b8aae498dbd828dfb1d288
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_320f7742b3e9dfbd183363c16439f447 |
| publicationDate |
2021-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020013094-A2 |
| titleOfInvention |
TOTALLY HUMAN NATURAL NEUTRALIZING MONOCLONAL ANTIBODY AGAINST TETANIC TOXIN AND ITS APPLICATIONS |
| abstract |
The present invention relates to native, fully human neutralizing monoclonal antibodies against tetanus toxin. The fully human neutralizing monoclonal antibodies native to tetanus toxin developed from the invention through a systematic high productivity platform that is specialized to identify and develop native human antibody. The neutralizing monoclonal antibodies described in the invention can be used in the prevention, treatment and testing of infection by Clostridium tetani. The fully human neutralizing monoclonal antibodies developed in the invention have a high affinity with the tetanus toxin, as well as having high neutralizing activities against the toxin, safe to use with high disease prevention efficacy, free from exogenous virus contamination, and are widely applicable to various human groups with strong industrial applications. |
| priorityDate |
2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |